Related Experiment Video
Updated: Jul 25, 2026
Myocardial Infarction and Functional Outcome Assessment in Pigs
Published on: April 25, 2014
[Dilren efficacy in postmyocardial infarction patients]
Insights
This study evaluated Diltiazem treatment in myocardial infarction (MI) survivors. Diltiazem showed efficacy in managing MI, with most patients improving and no fatal outcomes observed.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Myocardial infarction (MI) survivors require long-term management to prevent recurrence and improve outcomes.
- Assessing the efficacy and safety of pharmacological interventions is crucial for post-MI care.
Purpose of the Study:
- To evaluate the effectiveness and safety of Diltiazem in the treatment of survivors of primary macrofocal myocardial infarction.
- To determine optimal Diltiazem dosage regimens based on patient response and comorbidities like arterial hypertension.
Main Methods:
- A cohort of 25 survivors of primary macrofocal myocardial infarction were treated with Diltiazem for one year.
- Dosage adjustments were made: 180 mg for initial treatment, increased to 300 mg for patients with concomitant arterial hypertension.
- Patient outcomes, including improvement, deterioration, recurrent MI, and drug-induced complications, were monitored.
Main Results:
- No fatal outcomes were recorded during the one-year treatment period.
- 15 (60%) patients showed clinical improvement, while 4 (16%) experienced deterioration.
- Recurrent myocardial infarction occurred in 4 (16%) patients, and Diltiazem-induced complications were observed in 3 (12%) patients.
Conclusions:
- Diltiazem treatment appears to be a viable option for managing survivors of macrofocal myocardial infarction.
- Dosage titration, particularly in patients with arterial hypertension, may be necessary for optimal therapeutic response.
- While generally well-tolerated, careful monitoring for potential complications and recurrent events is warranted.
Abstract:
25 survivors of primary macrofocal myocardial infarction (MI) were treated for a year with children. The response in 9(36%) patients was achieved with a single dose 180 mg, in 16(64%) patients with concomitant arterial hypertension the dose was raised to 300 mg. No fatal outcomes were registered. Repeated IM developed in 4(16%) patients. 15(60%) patients improved, deterioration was seen in 4(16%) patients. Dilren-induced complications occurred in 3(12%) patients.
